Cwm, LLC Agios Pharmaceuticals, Inc. Transaction History

Cwm, LLC

$23.3 Billion
Q3 2024

A detailed history of Cwm, LLC transactions in Agios Pharmaceuticals, Inc. stock. As of the latest transaction made, Cwm, LLC holds 2,167 shares of AGIO stock, worth $128,069. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,167

Previous 331 554.68%

Holding current value

$128,069

Previous $14,000 585.71%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 08, 2024	BUY	$41.19 - $49.72 $75,624 - $91,285	1,836 Added 554.68%	2,167 $96,000
Q2 2024 Jul 09, 2024	BUY	$27.55 - $48.83 $4,463 - $7,910	162 Added 95.86%	331 $14,000
Q1 2024 Apr 05, 2024	BUY	$21.32 - $34.81 $234 - $382	11 Added 6.96%	169 $5,000
Q4 2023 Feb 01, 2024	BUY	$19.97 - $24.53 $2,616 - $3,213	131 Added 485.19%	158 $4,000
Q3 2023 Oct 11, 2023	BUY	$24.36 - $28.18 $462 - $535	19 Added 237.5%	27 $1,000
Q2 2023 Aug 03, 2023	SELL	$21.38 - $29.19 $128 - $175	-6 Reduced 42.86%	8 $0
Q1 2023 Apr 28, 2023	BUY	$21.74 - $30.93 $130 - $185	6 Added 75.0%	14 $0
Q4 2022 Feb 01, 2023	SELL	$24.81 - $31.52 $173 - $220	-7 Reduced 46.67%	8 $0
Q2 2022 Jul 28, 2022	BUY	$17.06 - $31.42 $136 - $251	8 Added 114.29%	15 $0
Q3 2019 Sep 14, 2021	BUY	$32.4 - $49.58 $226 - $347	7 New	7 $0
Q3 2019 Oct 22, 2019	SELL	$32.4 - $49.58 $226 - $347	-7 Closed	0 $0
Q2 2019 Sep 14, 2021	BUY	$46.17 - $68.1 $323 - $476	7 New	7 $0
Q2 2019 Jul 31, 2019	SELL	$46.17 - $68.1 $323 - $476	-7 Closed	0 $0
Q1 2019 Sep 02, 2021	BUY	$45.92 - $67.67 $275 - $406	6 Added 600.0%	7 $0
Q1 2019 Apr 22, 2019	BUY	$45.92 - $67.67 $45 - $67	1 New	1 $0

Others Institutions Holding AGIO

# of Institutions

232

Shares Held

58.1M

Call Options Held

403K

Put Options Held

469K

View Full List

About AGIOS PHARMACEUTICALS, INC.

Ticker AGIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,818,000
Market Cap $3.24B
Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...

More about AGIO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Account